Mvm
also invests · investor profileLondon, GB · 1 known investors
MVM is a healthcare-focused investment firm that provides growth equity to companies in medical technology, pharmaceuticals, diagnostics, digital health, life science tools, and contract research and manufacturing. Operating from Boston and London since 1997, it partners with management teams to scale differentiated healthcare products across global markets.
Also known as MVM Partners · MVM Partners LLP
Investors · 1
Company profile
researched Aug 2026MVM Partners LLP is an investment firm founded in 1997 that invests in healthcare and life sciences businesses, working with management teams to support the growth and scale of their companies across the United States and Europe. The firm operates from offices in Boston (Old City Hall, 45 School Street) and London, with team presence also cited in the San Francisco Bay Area.
The firm invests across healthcare sub-sectors including medical devices, pharmaceuticals, diagnostics, digital health, health IT, life science tools, contract research and contract manufacturing. It targets businesses with differentiated technology addressing unmet needs in large markets, and maintains a concentrated portfolio. MVM works with portfolio company management on organic growth, strategic acquisitions and establishing new standards of care.
Business model
MVM Partners manages a family of private investment funds on behalf of institutional limited partners, deploying capital into healthcare and life sciences companies and working with their management teams over long holding periods. Reported exits and portfolio events include Nalu Medical's acquisition by Boston Scientific and Paragon 28's acquisition by Zimmer Biomet.
As a private investment manager, MVM earns returns from its fund strategies and investments in portfolio companies.
Traction
MVM is reported to manage over $1 billion in assets. Recent investment activity includes a €32 million Series A growth investment in Avanzanite Bioscience (November 2025), participation in an $80 million Series B in ProVerum led by MVM (August 2025), a $37 million Series D in GT Medical Technologies (January 2025), and an investment in Neurent Medical (February 2026).
Latest developments
Reported activity includes an announced investment in Neurent Medical in February 2026, the November 2025 Avanzanite Bioscience Series A growth investment, and the August 2025 ProVerum Series B. Portfolio developments cited include FDA approval of ProVerum's ProVee System, Paratek Pharmaceuticals' acquisition of Optinose, and Zimmer Biomet's acquisition of Paragon 28.
▸Full profile — market position, go-to-market, geography, history
Market position
MVM Partners is described as a healthcare and life sciences specialist with nearly three decades of investing experience and a concentrated portfolio of high-growth companies, managing assets totaling over $1 billion.
The firm concentrates exclusively on healthcare and life sciences, favouring companies with differentiated technology and durable protection against competition, and takes an active role alongside management teams on growth and acquisition strategy.
Go-to-market
MVM sources investments directly and accepts inbound proposals at info@mvm.com; it invests across stages from seed and Series A through Series C and growth equity, typically writing checks of $20 million to $100 million per portfolio company with capacity for larger investments in select cases.
The firm invests in healthcare and life sciences companies, spanning medical devices, pharmaceuticals, diagnostics, digital health, health IT, life science tools, contract research and contract manufacturing organizations.
Geography
Headquartered in Boston, United States, with an office in London, United Kingdom and team members cited in the San Francisco Bay Area; the firm lists three offices in total. Its investment focus is primarily North America and Europe, with reach extended into the Middle East and Asia.
History
The firm was founded in 1997. It has raised a series of funds, including MVM Fund V, which closed at $325 million in 2020; MVM VI, recorded with a November 2022 close date; and MVM IV (2019), recorded with an April 2024 close date. A vehicle listed as "MVM" opened in December 2022 and is recorded as in market, with seven closed funds attributed to the firm.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 8
launches, deals, and filingsMVM Partners announced an investment in Neurent Medical.
MVM led a €32 million Series A growth investment in Avanzanite Bioscience, a commercial-stage European specialty pharma company focused on rare diseases and access to rare-disease medicines across Europe.
ProVerum, developer of the ProVee System for benign prostatic hyperplasia, closed an $80 million Series B led by MVM.
$80M source ↗
MVM reported a $37 million Series D investment in GT Medical Technologies, a developer whose therapy is cited as reducing brain tumor recurrence risk.
$37M source ↗
Fund MVM IV (2019) is listed with a close date of April 2024.
A fund listed as "MVM" is recorded with an open date of December 2022 and shown as in market.
MVM's Fund V closed at $325 million in 2020; a fund listed as MVM Fund V is recorded with a January 2020 close date.
$325M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureCompanies House · registry record
View on Companies House ↗- Registered name
- MVM LIMITED
- Company number
- 03351914
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 14 Apr 1997
- Registered office
- 38 Wigmore Street, Fourth Floor Offices, Suite 2, London, W1U 2RU
- Nature of business (SIC)
- 74990 — Non-trading company
- Previous names
- MVM (CIP) LIMITED (2000–2007)UK MEDICAL VENTURES (CARRIED INTEREST PARTNER) LIMITED (1997–2000)MILDNICE LIMITED (1997–1997)
- Accounts
- last made up to 31 Mar 2025 · next due 31 Dec 2026
- Confirmation statement
- last made up to 14 Apr 2026 · next due 28 Apr 2027
Current officers · 2
- Neil James Akhurst — director, appointed 17 Dec 2013
- Mvm Partners Llp — corporate director, appointed 11 Jul 2006
Source: Companies House public register · retrieved 9 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
▸Research sources · 6
primary sources listed
- MVM Partners | Institution Profile | Private Equity Internationalprivateequityinternational.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Mvm do?
- MVM Partners is a healthcare and life sciences investment firm founded in 1997, operating from Boston and London.
- Who are Mvm's investors?
- Mvm's investors include Tesi (Finnish Industry Investment Ltd).
- Where is Mvm headquartered?
- Mvm is headquartered in London, GB.